Li Zheng-Rui, Wang Yu-Feng, Zuo Chen- Rong, Men Jing-Sheng, Li Xin-Yuan, Luo Peng, Su Xiao-San, Sun Rui-Fen
College of Basic Medical Science , Yunnan University of Chinese Medicine, kunming, 650500, China.
School of Medicine, Shanghai Jiao Tong University, Shanghai, 200000, China.
BMC Cancer. 2025 May 13;25(1):863. doi: 10.1186/s12885-025-14264-z.
This meta-analysis systematically evaluated the effectiveness and safety of immune checkpoint inhibitors (ICIs) in treating advanced cervical cancer, emphasizing their potential as transformative therapeutic options in this complex clinical landscape.
EMBASE, Web of Science, PubMed, and the Cochrane Library were thoroughly searched for articles on the outcomes of ICIs in advanced cervical cancer patients. A pooled analysis was performed to evaluate the objective response rate (ORR: reported as an odds ratio (OR), progression-free survival (PFS; hazard ratio (HR), overall survival (OS; HR), and safety outcomes risk ratio (RR). Subgroup and sensitivity analyses were also conducted to identify potential sources of bias and heterogeneity.
Our meta-analysis included 5 studies involving 3,112 patients. Compared with standard therapies, treatment with immune checkpoint inhibitors (ICIs) significantly improved the objective response rate (ORR; OR = 1.68, 95% CI = 1.27-2.23), prolonged progression-free survival (PFS; HR = 0.72, 95% CI = 0.65-0.80), and extended overall survival (OS; HR = 0.69, 95% CI = 0.61-0.79). Subgroup analyses revealed potential predictors of treatment response. Moreover, ICIs exhibit a manageable safety profile, with adverse events consistent with known immune-related toxicities.
This meta-analysis highlights the promising efficacy and favourable safety profile of immune checkpoint inhibitors in advanced cervical cancer. These findings suggest a paradigm shift in treatment strategies, with ICIs emerging as a potential cornerstone therapy. Further research is warranted to elucidate optimal patient selection, combination therapies, and long-term outcomes. This study provides valuable insights for clinicians and researchers, paving the way for personalized and effective treatment approaches for advanced cervical cancer.
本荟萃分析系统评估了免疫检查点抑制剂（ICI）治疗晚期宫颈癌的有效性和安全性，强调了其在这一复杂临床领域作为变革性治疗选择的潜力。
全面检索了EMBASE、科学网、PubMed和考克兰图书馆，以查找有关ICI治疗晚期宫颈癌患者结局的文章。进行了汇总分析，以评估客观缓解率（ORR：报告为比值比（OR））、无进展生存期（PFS；风险比（HR））、总生存期（OS；HR）和安全性结局风险比（RR）。还进行了亚组分析和敏感性分析，以确定潜在的偏倚和异质性来源。
我们的荟萃分析纳入了5项研究，涉及3112例患者。与标准疗法相比，免疫检查点抑制剂（ICI）治疗显著提高了客观缓解率（ORR；OR = 1.68，95%CI = 1.27 - 2.23），延长了无进展生存期（PFS；HR = 0.72, 95%CI = 0.65 - 0.80），并延长了总生存期（OS；HR = 0.69, 95%CI = 0.61 - 0.79）。亚组分析揭示了治疗反应的潜在预测因素。此外，ICI表现出可控的安全性，不良事件与已知的免疫相关毒性一致。
本荟萃分析突出了免疫检查点抑制剂在晚期宫颈癌中具有前景的疗效和良好的安全性。这些发现表明治疗策略发生了范式转变，ICI成为潜在的基石疗法。有必要进一步研究以阐明最佳的患者选择、联合疗法和长期结局。本研究为临床医生和研究人员提供了有价值的见解，为晚期宫颈癌的个性化和有效治疗方法铺平了道路。
